Report
EUR 13.77 For Business Accounts Only

TESARO INCO. reduces its risk exposure and slightly improves to Neutral

The independent financial analyst theScreener just allocated a lower risk rating to TESARO INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 2 out of 4 possible stars. Its market behaviour, however, has slightly improved and can be qualified as moderately risky. theScreener considers that these elements merit an overall rating upgrade to Neutral. As of the analysis date October 5, 2018, the closing price was USD 42.88 and its expected value was estimated at USD 36.42.
Underlying
TESARO Inc.

TESARO is an oncology-focused biopharmaceutical company. The company acquires, in-licenses and develops oncology product candidates. The company has in-licensed and is developing oncology-related product candidates, including rolapitant, niraparib, and the product candidates under its immuno-oncology platform. The company's existing products and product candidates are: Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an oral poly polymerase inhibitor for the treatment of ovarian or breast cancers; and Immuno-Oncology Platform, which is engaged in the discovery and development of antibodies for several immuno-oncology targets.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch